BACKGROUND AND PURPOSE: Intracranial thrombus is a principal feature in most ischemic stroke, and thrombus location and size may correlate with outcome and response to thrombolytic therapy. EP-2104R is a fibrin-specific molecular MR agent that has previously been shown to enhance extracranial and venous sinus thrombi in animal models and, recently, in clinical trials. In this study, we examined whether this fibrin-specific MR probe could noninvasively characterize intracranial arterial thrombi. METHODS: Embolic stroke was induced in adult rats by occlusion of the right internal carotid artery with an aged thrombus. We used diffusion-weighted imaging, time of flight angiography, and high-resolution 3-dimensional T1-weighted MRI at 4.7 T before and after use of contrast agents EP-2104R (n=6) and gadopentetate dimeglumine (n=5). RESULTS: In all animals, MR angiography revealed a flow deficit and diffusion-weighted imaging showed hyperintensity consistent with ischemia. Using EP-2104R-enhanced MRI, we saw occlusive thrombi and vessel wall enhancement in all 6 animals with high contrast to noise relative to blood, whereas gadopentetate dimeglumine-injected animals showed no occlusive thrombus or vessel wall enhancement. The concentration of gadolinium in the thrombus after EP-2104R was 18 times that in the blood pool. CONCLUSIONS: EP-2104R-enhanced MRI successfully identifies intracranial thrombus in a rat embolic stroke model.
BACKGROUND AND PURPOSE:Intracranial thrombus is a principal feature in most ischemic stroke, and thrombus location and size may correlate with outcome and response to thrombolytic therapy. EP-2104R is a fibrin-specific molecular MR agent that has previously been shown to enhance extracranial and venous sinus thrombi in animal models and, recently, in clinical trials. In this study, we examined whether this fibrin-specific MR probe could noninvasively characterize intracranial arterial thrombi. METHODS:Embolic stroke was induced in adult rats by occlusion of the right internal carotid artery with an aged thrombus. We used diffusion-weighted imaging, time of flight angiography, and high-resolution 3-dimensional T1-weighted MRI at 4.7 T before and after use of contrast agents EP-2104R (n=6) and gadopentetate dimeglumine (n=5). RESULTS: In all animals, MR angiography revealed a flow deficit and diffusion-weighted imaging showed hyperintensity consistent with ischemia. Using EP-2104R-enhanced MRI, we saw occlusive thrombi and vessel wall enhancement in all 6 animals with high contrast to noise relative to blood, whereas gadopentetate dimeglumine-injected animals showed no occlusive thrombus or vessel wall enhancement. The concentration of gadolinium in the thrombus after EP-2104R was 18 times that in the blood pool. CONCLUSIONS:EP-2104R-enhanced MRI successfully identifies intracranial thrombus in a ratembolic stroke model.
Authors: Marcus Katoh; Patrick Haage; Andrea J Wiethoff; Rolf W Günther; Arno Bücker; Josef Tacke; Elmar Spuentrup Journal: Invest Radiol Date: 2009-03 Impact factor: 6.016
Authors: Marc Sirol; Valentin Fuster; Juan J Badimon; John T Fallon; Pedro R Moreno; Jean-François Toussaint; Zahi A Fayad Journal: Circulation Date: 2005-09-06 Impact factor: 29.690
Authors: S Flacke; S Fischer; M J Scott; R J Fuhrhop; J S Allen; M McLean; P Winter; G A Sicard; P J Gaffney; S A Wickline; G M Lanza Journal: Circulation Date: 2001-09-11 Impact factor: 29.690
Authors: Megan C Leary; Chelsea S Kidwell; J Pablo Villablanca; Sidney Starkman; Reza Jahan; Gary R Duckwiler; Y Pierre Gobin; Steven Sykes; Kristi J Gough; Katrina Ferguson; Jennifer N Llanes; Rinat Masamed; Margaret Tremwel; Bruce Ovbiagele; Paul M Vespa; Fernando Vinuela; Jeffrey L Saver Journal: Stroke Date: 2003-10-30 Impact factor: 7.914
Authors: S F Rosebrough; Z D Grossman; J G McAfee; B J Kudryk; G Subramanian; C A Ritter-Hrncirik; L S Witanowski; G Tillapaugh-Fay; E Urrutia Journal: Radiology Date: 1987-02 Impact factor: 11.105
Authors: René M Botnar; Arno Buecker; Andrea J Wiethoff; Edward C Parsons; Marcus Katoh; George Katsimaglis; Robert M Weisskoff; Randall B Lauffer; Philip B Graham; Rolf W Gunther; Warren J Manning; Elmar Spuentrup Journal: Circulation Date: 2004-07-06 Impact factor: 29.690
Authors: Alan R Moody; Rachael E Murphy; Paul S Morgan; Anne L Martel; G S Delay; Steve Allder; Shane T MacSweeney; William G Tennant; John Gladman; John Lowe; Beverley J Hunt Journal: Circulation Date: 2003-06-09 Impact factor: 29.690
Authors: Andrew F Kolodziej; Shrikumar A Nair; Philip Graham; Thomas J McMurry; Robert C Ladner; Charles Wescott; Daniel J Sexton; Peter Caravan Journal: Bioconjug Chem Date: 2012-02-09 Impact factor: 4.774
Authors: L Chaabane; L Tei; L Miragoli; L Lattuada; M von Wronski; F Uggeri; V Lorusso; S Aime Journal: Mol Imaging Biol Date: 2015-12 Impact factor: 3.488
Authors: Ilknur Ay; Francesco Blasi; Tyson A Rietz; Nicholas J Rotile; Sreekanth Kura; Anna Liisa Brownell; Helen Day; Bruno L Oliveira; Richard J Looby; Peter Caravan Journal: Circ Cardiovasc Imaging Date: 2014-04-28 Impact factor: 7.792
Authors: Katie L Ciesienski; Yan Yang; Ilknur Ay; Daniel B Chonde; Galen S Loving; Tyson A Rietz; Ciprian Catana; Peter Caravan Journal: Mol Pharm Date: 2013-01-30 Impact factor: 4.939
Authors: Eszter Boros; Elena Rybak-Akimova; Jason P Holland; Tyson Rietz; Nicholas Rotile; Francesco Blasi; Helen Day; Reza Latifi; Peter Caravan Journal: Mol Pharm Date: 2013-12-11 Impact factor: 4.939
Authors: Bruno L Oliveira; Francesco Blasi; Tyson A Rietz; Nicholas J Rotile; Helen Day; Peter Caravan Journal: J Nucl Med Date: 2015-08-06 Impact factor: 10.057